Novel Aptamers Targeting Sclerostin Loop3 Improve Skeletal and Muscle Properties Without Adverse Cardiovascular Effects in Orchiectomized Mice., PMID:40464222
Role of Sclerostin in Cardiovascular System., PMID:40429697
Research Progress on the Influence of Novel Targeted Drugs for Osteoporosis on Glucose Metabolism., PMID:40149867
Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment., PMID:39767786
Activation of connexin hemichannels enhances mechanosensitivity and anabolism in disused and aged bone., PMID:39641271
Effect of anti-sclerostin antibody on orthodontic tooth movement in ovariectomized rats., PMID:39581932
Compact Arterial Monitoring Device Use in Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): A Simple Validation Study in Swine., PMID:39493181
A mechanism of action-reflective, dual cell-based bioassay for determining the bioactivity of sclerostin-neutralizing antibodies., PMID:39389544
Sclerostin Antibody-Loaded Dense Collagen Hydrogels Promote Critical-Size Bone Defect Repair., PMID:39269225
Sclerostin antibody corrects periodontal disease in type 2 diabetic mice., PMID:39171525
The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies., PMID:39078512
AI-based 3D-QSAR model of FDA-approved repurposed drugs for inhibiting sclerostin., PMID:39031396
Role of sclerostin deletion in bisphosphonate-induced osteonecrosis of the jaw., PMID:39019131
Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab-a sclerostin neutralizing antibody., PMID:38982734
Sclerostin antibody enhances implant osseointegration in bone with Col1a1 mutation., PMID:38876270
Increased endothelial sclerostin caused by elevated DSCAM mediates multiple trisomy 21 phenotypes., PMID:38828726
A practical approach for anabolic treatment of bone fragility with romosozumab., PMID:38789679
Sclerostin blockade inhibits bone resorption through PDGF receptor signaling in osteoblast lineage cells., PMID:38713511
Affinity targeting of therapeutic proteins to the bone surface-local delivery of sclerostin-neutralizing antibody enhances efficacy., PMID:38526976
Protein profiling in systemic sclerosis patients with different pulmonary complications using proteomic antibody microarray., PMID:38233947
Τhe story of sclerostin inhibition: the past, the present, and the future., PMID:38170438
Romosozumab in osteoporosis: yesterday, today and tomorrow., PMID:37759285
Wnt signaling pathway and sclerostin in the development of atherosclerosis and vascular calcification., PMID:37676098
Loss of Nmp4 enhances bone gain from sclerostin antibody administration., PMID:37660938
Sclerostin and Cardiovascular Disease., PMID:37490188
The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts., PMID:37108735
Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma., PMID:36987921
Effect of sclerostin inactivation in a mouse model of severe dominant osteogenesis imperfecta., PMID:36973504
Inhibition of RANKL Expression in Osteocyte-like Differentiated Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment., PMID:36971322
Early sclerostin assessment in frail elderly patients with sepsis: insights on short- and long-term mortality prediction., PMID:36943596
Sostdc1 Suppression in the Absence of Sclerostin Potentiates Anabolic Action of Cortical Bone in Mice., PMID:36891756
Novel insights on the effect of sclerostin on bone and other organs., PMID:36802398
Updates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone-Vascular paradox, a therapeutic target, and a biomarker., PMID:36776982
Antibodies to sclerostin or G-CSF receptor partially eliminate bone or marrow adipocyte loss, respectively, following vertical sleeve gastrectomy., PMID:36709915
A high-throughput biomimetic bone-on-a-chip platform with artificial intelligence-assisted image analysis for osteoporosis drug testing., PMID:36684077
Targeted postnatal knockout of Sclerostin using a bone-targeted adeno-associated viral vector increases bone anabolism and decreases canalicular density., PMID:36462771
Sclerostin antibody promotes bone formation through the Wnt/β-catenin signaling pathway in femoral trochlear after patellar instability., PMID:36379907
Sclerostin ablation prevents aortic valve stenosis in mice., PMID:36240434
Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders., PMID:35982318
Sclerostin is a promising therapeutic target for oral inflammation and regenerative dentistry., PMID:35562828
Sclerostin immunohistochemical staining in surgically treated giant cell tumor of bone., PMID:35446992
Evidence for the major contribution of remodeling-based bone formation in sclerostin-deficient mice., PMID:35381389
In vitro and in vivo Repair Effects of the NCF-Col-NHA Aerogel Scaffold Loaded With SOST Monoclonal Antibody and SDF-1 in Steroid-Induced Osteonecrosis., PMID:35372296
Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice., PMID:35278242
Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis., PMID:35264832
The Role of Sclerostin in Bone Diseases., PMID:35160258
Sclerostin Protects Against Vascular Calcification Development in Mice., PMID:35038187
Combining sclerostin neutralization with tissue engineering: An improved strategy for craniofacial bone repair., PMID:34875361
Sclerostin Depletion Induces Inflammation in the Bone Marrow of Mice., PMID:34502021
Low Levels of Serum Sclerostin in Adult Patients With Tumor-Induced Osteomalacia Compared With X-linked Hypophosphatemia., PMID:34363479
For research use only. Not for human or drug use.
